Pub Date : 2021-07-27DOI: 10.17749/2070-4909/FARMAKOEKONOMIKA.2021.096
A. Chuchalin, I. Torshin, O. Gromova
A range of 6700 publications from the PubMed database on the association of micronutrient supply and results of antibacterial and antiviral vaccination was reviewed by the method of topologic and metric analysis. This method allows for a selection of features (i.e. key words) by their informativity, the establishment of the most informative that provide the basis for “synthetic” features and algorithms, or the classification of the reviewed text by the relevance to the subject of the study. The results of fundamental studies showed that folates, vitamins A, D, and B12 are the regulators of mitosis of T and B-lymphocytes that exert the functions of the acquired immunity. Such microelements as zinc, iron, selenium, manganese, and omega-3 polyunsaturated fatty acid support the functioning of T and B-lymphocytes (energy metabolism, intracellular signal transmission, and transcription). Clinical studies showed that the support of vaccination with the specified micronutrients not only increases the titre of the respective antibodies to viral and bacterial pathogens but can also prevent unfavorable effects from vaccination. The administration of micronutrients before and after vaccination will contribute to a decrease in the mortality rate and severity of the pathology development (in case of disease). A systematic analysis allowed the authors to determine the perspectives of the proposed measures for an increase in the effectiveness and safety of vaccines, including COVID-19. Additional micronutrient supply contributes to an increase in the effectiveness and safety of vaccination. The application of specialized vitamin and mineral complexes during vaccination is economically feasible and reduces the vaccination risks for patients with polyhypoavitaminoses.
{"title":"Systematic computer analysis of published literature on nutritional support for vaccination","authors":"A. Chuchalin, I. Torshin, O. Gromova","doi":"10.17749/2070-4909/FARMAKOEKONOMIKA.2021.096","DOIUrl":"https://doi.org/10.17749/2070-4909/FARMAKOEKONOMIKA.2021.096","url":null,"abstract":"A range of 6700 publications from the PubMed database on the association of micronutrient supply and results of antibacterial and antiviral vaccination was reviewed by the method of topologic and metric analysis. This method allows for a selection of features (i.e. key words) by their informativity, the establishment of the most informative that provide the basis for “synthetic” features and algorithms, or the classification of the reviewed text by the relevance to the subject of the study. The results of fundamental studies showed that folates, vitamins A, D, and B12 are the regulators of mitosis of T and B-lymphocytes that exert the functions of the acquired immunity. Such microelements as zinc, iron, selenium, manganese, and omega-3 polyunsaturated fatty acid support the functioning of T and B-lymphocytes (energy metabolism, intracellular signal transmission, and transcription). Clinical studies showed that the support of vaccination with the specified micronutrients not only increases the titre of the respective antibodies to viral and bacterial pathogens but can also prevent unfavorable effects from vaccination. The administration of micronutrients before and after vaccination will contribute to a decrease in the mortality rate and severity of the pathology development (in case of disease). A systematic analysis allowed the authors to determine the perspectives of the proposed measures for an increase in the effectiveness and safety of vaccines, including COVID-19. Additional micronutrient supply contributes to an increase in the effectiveness and safety of vaccination. The application of specialized vitamin and mineral complexes during vaccination is economically feasible and reduces the vaccination risks for patients with polyhypoavitaminoses.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133303783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-27DOI: 10.17749/2070-4909/FARMAKOEKONOMIKA.2021.078
I. Torshin, O. Gromova, A. Chuchalin, Y. Zhuravlev
Background. So-called rational drug design is suboptimal when it comes to finding effective and safe drug-based treatment for COVID-19. Another approach seems promising: to reprofile the pharmaceuticals registered in the Anatomical, Therapeutic, and Chemical Classifier (ATC).Material and methods. Chemoreactome screening, a method that simulates the results of inhibiting viral growth in a cell culture, models the effects of pharmaceuticals on the human virome, and estimates the adverse effects of medicines, was used to reprofile about 2700 pharmaceuticals from the ATC. The information technology behind chemoreactome analysis is based on the topological recognition theory advanced by the Institute of Pharmaceutical Informatics, Federal Research Center for Informatics and Control, Russian Academy of Sciences.Results. Sixty two pharmaceuticals and 20 micronutrients were found to have a pronounced antiviral effect with minimal side effects. Comparison against data of basic research and clinical trials showed 31 out of 62 pharmaceuticals to have been independently confirmed usable in COVID-19 treatment. These inhibit coronaviral proteins and/or function as adaptogenic molecules that improve the functioning of cells exposed to viral stress. Glucosamine sulfate was found to have the best safety profile and minimum effects on the healthy human virome out of all the tested anticoronaviral micronutrients.Conclusions. Reprofiling of pharmaceuticals registered in the ATC could significantly speed up the search for more effective and safer drugbased COVID-19 treatments. Several micronutrients show promise for long-term coronavirus prevention, especially in the elderly.
{"title":"Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy","authors":"I. Torshin, O. Gromova, A. Chuchalin, Y. Zhuravlev","doi":"10.17749/2070-4909/FARMAKOEKONOMIKA.2021.078","DOIUrl":"https://doi.org/10.17749/2070-4909/FARMAKOEKONOMIKA.2021.078","url":null,"abstract":"Background. So-called rational drug design is suboptimal when it comes to finding effective and safe drug-based treatment for COVID-19. Another approach seems promising: to reprofile the pharmaceuticals registered in the Anatomical, Therapeutic, and Chemical Classifier (ATC).Material and methods. Chemoreactome screening, a method that simulates the results of inhibiting viral growth in a cell culture, models the effects of pharmaceuticals on the human virome, and estimates the adverse effects of medicines, was used to reprofile about 2700 pharmaceuticals from the ATC. The information technology behind chemoreactome analysis is based on the topological recognition theory advanced by the Institute of Pharmaceutical Informatics, Federal Research Center for Informatics and Control, Russian Academy of Sciences.Results. Sixty two pharmaceuticals and 20 micronutrients were found to have a pronounced antiviral effect with minimal side effects. Comparison against data of basic research and clinical trials showed 31 out of 62 pharmaceuticals to have been independently confirmed usable in COVID-19 treatment. These inhibit coronaviral proteins and/or function as adaptogenic molecules that improve the functioning of cells exposed to viral stress. Glucosamine sulfate was found to have the best safety profile and minimum effects on the healthy human virome out of all the tested anticoronaviral micronutrients.Conclusions. Reprofiling of pharmaceuticals registered in the ATC could significantly speed up the search for more effective and safer drugbased COVID-19 treatments. Several micronutrients show promise for long-term coronavirus prevention, especially in the elderly.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"34 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114006791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-27DOI: 10.17749/2070-4909/farmakoekonomika.2021.094
D. M. Medvedeva, I. Narkevich, O. D. Nemyatykh
Objective: to analyze the availability and affordability of pharmaceuticals for children in need of palliative care.Materials and methods. The price, affordability and physical availability of pharmaceuticals for children in need of palliative care were analyzed in accordance with the Health Action International guidelines of the World Health Organization. Linear distribution index (LDI) was calculated to produce the best estimates of availability. Research data was sourced from AlphaRM (as of April 26, 2021) and International Medicine Reference Piece Data. The data array was based on the fiscal data provided by pharmacies. The research was carried out on the total population of pharmacies in the Russian Federation (69,050 pharmacies) and in St. Petersburg (1986 pharmacies).Results. Pharmaceutical price and affordability estimates show that low-priced generics, which cover over 75% of the whole range, have the most optimal median value of the median price ratio (MPR<1) on top of low affordability ratios (AR<1). Ibuprofen, paracetamol, gabapentin, diazepam, morphine, midazolam, and carbamazepine were found to be the least affordable medications, price-wise (MPR>1). Midazolam (AR=2.494), morphine (AR=2.324), and celecoxib (AR=1.373) had low affordability. Notably, prescription-based pharmaceuticals such as diazepam, midazolam, tramadol, morphine, and fentanyl had the lowest physical availability scores (LDI<3%) in the Russian market compared to the relatively high scores of over-the-counter drugs (LDI>60%).Conclusions. The results call for better organizational action in the pharmaceutical industry to provide due drug regimens to children in need of palliative care.
{"title":"Analysis of the availability and affordability of pharmaceuticals for children in need of palliative care","authors":"D. M. Medvedeva, I. Narkevich, O. D. Nemyatykh","doi":"10.17749/2070-4909/farmakoekonomika.2021.094","DOIUrl":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.094","url":null,"abstract":"Objective: to analyze the availability and affordability of pharmaceuticals for children in need of palliative care.Materials and methods. The price, affordability and physical availability of pharmaceuticals for children in need of palliative care were analyzed in accordance with the Health Action International guidelines of the World Health Organization. Linear distribution index (LDI) was calculated to produce the best estimates of availability. Research data was sourced from AlphaRM (as of April 26, 2021) and International Medicine Reference Piece Data. The data array was based on the fiscal data provided by pharmacies. The research was carried out on the total population of pharmacies in the Russian Federation (69,050 pharmacies) and in St. Petersburg (1986 pharmacies).Results. Pharmaceutical price and affordability estimates show that low-priced generics, which cover over 75% of the whole range, have the most optimal median value of the median price ratio (MPR<1) on top of low affordability ratios (AR<1). Ibuprofen, paracetamol, gabapentin, diazepam, morphine, midazolam, and carbamazepine were found to be the least affordable medications, price-wise (MPR>1). Midazolam (AR=2.494), morphine (AR=2.324), and celecoxib (AR=1.373) had low affordability. Notably, prescription-based pharmaceuticals such as diazepam, midazolam, tramadol, morphine, and fentanyl had the lowest physical availability scores (LDI<3%) in the Russian market compared to the relatively high scores of over-the-counter drugs (LDI>60%).Conclusions. The results call for better organizational action in the pharmaceutical industry to provide due drug regimens to children in need of palliative care.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125603478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-27DOI: 10.17749/2070-4909/farmakoekonomika.2021.031
M. Chernyavskaya, I. Narkevich
Objective: to evaluate the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome based on survey results.Material and methods. The authors analyzed 394 surveys of pharmaceutical specialists in Saint-Petersburg. The survey consisted of 13 questions, covered the personal characteristics of the participants (age, education, professional experience) and their knowledge about special medicines and food supplements to control climacteric symptoms, indications, and contraindications.Results. The results showed that pharmaceutical specialists saw the difference between combined oral contraceptives and menopausal hormone therapy, but they do not know about the protective cardiovascular effects of menopausal hormone therapy. Most specialists consider menopausal hormone therapy more effective than phytoestrogens, but they have no idea how it works. For most of them, there is hardly any difference between various classes of phytoestrogens. In their opinion, medical representatives and scientific conferences are the main providers of medical information.Conclusion. The analysis of the level of awareness of pharmaceutical specialists about the pharmacotherapy of menopausal syndrome based on the results of the survey revealed insufficient knowledge among pharmacy workers on a number of fundamental issues. Therefore, it is necessary to develop methodological recommendations on menopausal hormone therapy preparations and phytoestrogens-based drugs for pharmaceutical specialists who act as an important intermediate between a doctor and a patient.
{"title":"Survey-based evaluation of the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome","authors":"M. Chernyavskaya, I. Narkevich","doi":"10.17749/2070-4909/farmakoekonomika.2021.031","DOIUrl":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.031","url":null,"abstract":"Objective: to evaluate the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome based on survey results.Material and methods. The authors analyzed 394 surveys of pharmaceutical specialists in Saint-Petersburg. The survey consisted of 13 questions, covered the personal characteristics of the participants (age, education, professional experience) and their knowledge about special medicines and food supplements to control climacteric symptoms, indications, and contraindications.Results. The results showed that pharmaceutical specialists saw the difference between combined oral contraceptives and menopausal hormone therapy, but they do not know about the protective cardiovascular effects of menopausal hormone therapy. Most specialists consider menopausal hormone therapy more effective than phytoestrogens, but they have no idea how it works. For most of them, there is hardly any difference between various classes of phytoestrogens. In their opinion, medical representatives and scientific conferences are the main providers of medical information.Conclusion. The analysis of the level of awareness of pharmaceutical specialists about the pharmacotherapy of menopausal syndrome based on the results of the survey revealed insufficient knowledge among pharmacy workers on a number of fundamental issues. Therefore, it is necessary to develop methodological recommendations on menopausal hormone therapy preparations and phytoestrogens-based drugs for pharmaceutical specialists who act as an important intermediate between a doctor and a patient.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133912114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-27DOI: 10.17749/2070-4909/farmakoekonomika.2021.051
A. B. Ismoilova, N. M. Sultanbaeva, A. Abdurakhmanov, Sh. Z. Umarova, D. Dzhalalova, S. Dzhalalov
Objective: comparative systematic analysis of clinical trials of staged and simultaneous approaches in the surgical treatment of combined carotid and coronary stenosis based on the literature search.Material and methods. A systematic literature search was performed in PubMed/MEDLINE, Google Scholar and Scopus using predefined acceptance criteria. To compare data of simultaneous and staged surgery cumulative indicators of heart attack, stroke and mortality, expressed as percentages and absolute numbers, were analyzed; the Mantel–Hensel formula and the χ2 method were used to assess the relative risk of major adverse cardio-cerebral events development and mortality.Results. The analysis included 7 studies containing one intervention (4 simultaneous and 3 stage methods). The risk of developing myocardial infarction was RR 0.13 (95% CI 0.02–0.67) for simultaneous tactics, and RR 7.79 (95% CI 1.5–40.43) for staged tactics (p˂0.005). The risk of stroke developing was RR 1.29 (95% CI 0.56–2.99) for a simultaneous approach, and RR 0.78 (95% CI 0.33–1.8) for stage approach (p˃0.05). The risk of mortality was RR 0.77 (95% CI 0.31–1.88) for simultaneous procedures, and RR 1.3 (95% CI 0.53–3.18) for staged procedures (p˃0.05).Conclusion. Staged tactics for combined carotid and coronary stenosis may be accompanied by a significantly higher risk of myocardial infarction. There was no statistically significant difference between the groups in terms of the risk of stroke and mortality, but there was a trend towards a higher risk of stroke in the simultaneous group and a higher risk of death from all causes in the staged group.
目的:在文献检索的基础上，对分阶段入路与同步入路手术治疗颈动脉冠状动脉合并狭窄的临床试验进行比较系统分析。材料和方法。在PubMed/MEDLINE、Google Scholar和Scopus中使用预定义的接受标准进行系统的文献检索。比较同期手术和分期手术的心脏病发作、中风和死亡率的累积指标，以百分比和绝对数字表示;采用Mantel-Hensel公式和χ2方法对主要心脑不良事件发生的相对危险度和死亡率进行评估。该分析包括7项研究，其中包括1项干预(4项同时和3阶段方法)。同时策略发生心肌梗死的风险RR为0.13 (95% CI 0.02-0.67)，分阶段策略的风险RR为7.79 (95% CI 1.5-40.43) (p小于0.005)。同时入路卒中发生风险RR为1.29 (95% CI 0.56 ~ 2.99)，分期入路卒中发生风险RR为0.78 (95% CI 0.33 ~ 1.8) (p < 0.05)。同期手术的死亡率RR为0.77 (95% CI 0.31 ~ 1.88)，分期手术的死亡率RR为1.3 (95% CI 0.53 ~ 3.18) (p < 0.05)。分阶段治疗颈动脉和冠状动脉合并狭窄可能伴随心肌梗死的风险显著增高。在卒中风险和死亡率方面，两组之间没有统计学上的显著差异，但同时组的卒中风险较高，分阶段组的各种原因死亡风险较高。
{"title":"Comparative effectiveness of simultaneous and staged operations in patients with atherosclerotic lesions of carotid and coronary arteries","authors":"A. B. Ismoilova, N. M. Sultanbaeva, A. Abdurakhmanov, Sh. Z. Umarova, D. Dzhalalova, S. Dzhalalov","doi":"10.17749/2070-4909/farmakoekonomika.2021.051","DOIUrl":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.051","url":null,"abstract":"Objective: comparative systematic analysis of clinical trials of staged and simultaneous approaches in the surgical treatment of combined carotid and coronary stenosis based on the literature search.Material and methods. A systematic literature search was performed in PubMed/MEDLINE, Google Scholar and Scopus using predefined acceptance criteria. To compare data of simultaneous and staged surgery cumulative indicators of heart attack, stroke and mortality, expressed as percentages and absolute numbers, were analyzed; the Mantel–Hensel formula and the χ2 method were used to assess the relative risk of major adverse cardio-cerebral events development and mortality.Results. The analysis included 7 studies containing one intervention (4 simultaneous and 3 stage methods). The risk of developing myocardial infarction was RR 0.13 (95% CI 0.02–0.67) for simultaneous tactics, and RR 7.79 (95% CI 1.5–40.43) for staged tactics (p˂0.005). The risk of stroke developing was RR 1.29 (95% CI 0.56–2.99) for a simultaneous approach, and RR 0.78 (95% CI 0.33–1.8) for stage approach (p˃0.05). The risk of mortality was RR 0.77 (95% CI 0.31–1.88) for simultaneous procedures, and RR 1.3 (95% CI 0.53–3.18) for staged procedures (p˃0.05).Conclusion. Staged tactics for combined carotid and coronary stenosis may be accompanied by a significantly higher risk of myocardial infarction. There was no statistically significant difference between the groups in terms of the risk of stroke and mortality, but there was a trend towards a higher risk of stroke in the simultaneous group and a higher risk of death from all causes in the staged group.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130960947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-27DOI: 10.17749/2070-4909/farmakoekonomika.2021.054
E. Fedorova, D. O. Afanasyev, A. Sokolov, M. Lazarev
Objective: identification of the relationship between the news coverage of global diseases and the dynamics of the return on shares of the pharmaceutical sector for Russia and the United States.Material and methods. The empirical base of the study includes more than 700 thousand tweets on Ebola and COVID-19 in Russian and English, news of the RBC news agency. The sentiment of the text was assessed on the basis of five English and four Russian-language dictionaries, the influence of fundamental and textual variables on the profitability of pharmaceutical companies' shares was carried out using the ARMAX-GARCH econometric model.Results. It has been proven that the dynamics of the stock index of pharmaceutical companies is explained by fundamental (economic) and sentimental factors. News of any epidemics negatively affects the pharmaceutical sector in the US and Russia, that is, there are no industries that benefit from this situation. Pandemic news affects US pharmaceutical companies more than Russian companies. The effect of news influence depends on the level of spread of the disease. News influences not only at the moment of their publication, but also after: there is a "delayed effect". Ebola news affects the American pharmaceutical market for 2 weeks, and the dynamics of the increase in influence can be traced. News on the COVID pandemic amplifies its impact during 1 week for the Russian pharmaceutical market and for 2 weeks for the US pharmaceutical companies. As for news sources, the elastic network has identified more significant variables based on publications from RBC; therefore, Internet publications generate more publicity, shaping a more significant overall sentiment in the markets.Conclusion. The models developed in the framework of the study and the economic conclusions obtained have not only theoretical, but also practical significance, and can also be used for further research in this area. It is possible to give recommendations on the practical use of dictionaries to assess the sentiment of the text. In our study, the elastic network method chose the Loughran–McDonald dictionary for evaluating economic texts in English and the EcSentiThemeLex dictionary (designed in R and Python programming environments). Avenues for further investigation may include analysis of other sources of information about the pandemic.
{"title":"Impact of disease information (Ebola and COVID-19) on the pharmaceutical sector in Russia and USA","authors":"E. Fedorova, D. O. Afanasyev, A. Sokolov, M. Lazarev","doi":"10.17749/2070-4909/farmakoekonomika.2021.054","DOIUrl":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.054","url":null,"abstract":"Objective: identification of the relationship between the news coverage of global diseases and the dynamics of the return on shares of the pharmaceutical sector for Russia and the United States.Material and methods. The empirical base of the study includes more than 700 thousand tweets on Ebola and COVID-19 in Russian and English, news of the RBC news agency. The sentiment of the text was assessed on the basis of five English and four Russian-language dictionaries, the influence of fundamental and textual variables on the profitability of pharmaceutical companies' shares was carried out using the ARMAX-GARCH econometric model.Results. It has been proven that the dynamics of the stock index of pharmaceutical companies is explained by fundamental (economic) and sentimental factors. News of any epidemics negatively affects the pharmaceutical sector in the US and Russia, that is, there are no industries that benefit from this situation. Pandemic news affects US pharmaceutical companies more than Russian companies. The effect of news influence depends on the level of spread of the disease. News influences not only at the moment of their publication, but also after: there is a \"delayed effect\". Ebola news affects the American pharmaceutical market for 2 weeks, and the dynamics of the increase in influence can be traced. News on the COVID pandemic amplifies its impact during 1 week for the Russian pharmaceutical market and for 2 weeks for the US pharmaceutical companies. As for news sources, the elastic network has identified more significant variables based on publications from RBC; therefore, Internet publications generate more publicity, shaping a more significant overall sentiment in the markets.Conclusion. The models developed in the framework of the study and the economic conclusions obtained have not only theoretical, but also practical significance, and can also be used for further research in this area. It is possible to give recommendations on the practical use of dictionaries to assess the sentiment of the text. In our study, the elastic network method chose the Loughran–McDonald dictionary for evaluating economic texts in English and the EcSentiThemeLex dictionary (designed in R and Python programming environments). Avenues for further investigation may include analysis of other sources of information about the pandemic.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"268 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124349087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-26DOI: 10.17749/2070-4909/farmakoekonomika.2021.093
A. D. Ermolaeva, V. Krysanova, T. Ermolaeva, K. I. Polyakova, K. Kokushkin
Objective: scientific rationale of changing approaches to medical care payment for hospitalization of patients suffering from severe asthma (SA) that require the prescription of biologic disease-modifying drugs (bDMDs) within the constraints of diagnosis-related groups (DRGs) on the level of the Moscow Region.Material and methods. For the federal model regional adaptation, the authors used the mechanism of subgroups selection in the structure of basic DRG No. 336 st36.003 and No. 139 ds36.004 “Treatment with biologic disease-modifying drugs and selective immunosuppressants” in the round-the-clock (RH) and day-time hospital (DH). Budget impact analysis (BIA) was performed to provide scientific and economic feasibility for the improvement of medical care payment for bDMDs proscribed to patients with SA within DRG at the level of the Moscow Region.Results. The analysis of cost of drug therapy and medical services per 1 case of hospitalization of patients with SA, that required bDMDs therapy, considering the classification criterion (international nonproprietary name of drugs and drug therapy regimens), showed 10 subgroups in DRG No. 336 st36.003 (level 1) and 9 subgroups in DRG No. 139 ds36.004. Expert estimates on the rate of hospitalizations and drug dosage regimen indicated for patients with SA were used to calculate the relative cost weights (CW). The highest CW was observed in the subgroup that received benralizumab in RH (CW=7.46) and in DH (CW=12.08) conditions. BIA demonstrated 110,103,901.53 rubles (or 31%) budget savings for the health care system of the Moscow Region.Conclusion. The implementation of the adapted DRG federal model in the conditions of the health care system of Moscow Region is an economically feasible approach to the organization of the inpatient medical care provided to patients with SA needing bDMDs prescription.
{"title":"Medical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region","authors":"A. D. Ermolaeva, V. Krysanova, T. Ermolaeva, K. I. Polyakova, K. Kokushkin","doi":"10.17749/2070-4909/farmakoekonomika.2021.093","DOIUrl":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.093","url":null,"abstract":"Objective: scientific rationale of changing approaches to medical care payment for hospitalization of patients suffering from severe asthma (SA) that require the prescription of biologic disease-modifying drugs (bDMDs) within the constraints of diagnosis-related groups (DRGs) on the level of the Moscow Region.Material and methods. For the federal model regional adaptation, the authors used the mechanism of subgroups selection in the structure of basic DRG No. 336 st36.003 and No. 139 ds36.004 “Treatment with biologic disease-modifying drugs and selective immunosuppressants” in the round-the-clock (RH) and day-time hospital (DH). Budget impact analysis (BIA) was performed to provide scientific and economic feasibility for the improvement of medical care payment for bDMDs proscribed to patients with SA within DRG at the level of the Moscow Region.Results. The analysis of cost of drug therapy and medical services per 1 case of hospitalization of patients with SA, that required bDMDs therapy, considering the classification criterion (international nonproprietary name of drugs and drug therapy regimens), showed 10 subgroups in DRG No. 336 st36.003 (level 1) and 9 subgroups in DRG No. 139 ds36.004. Expert estimates on the rate of hospitalizations and drug dosage regimen indicated for patients with SA were used to calculate the relative cost weights (CW). The highest CW was observed in the subgroup that received benralizumab in RH (CW=7.46) and in DH (CW=12.08) conditions. BIA demonstrated 110,103,901.53 rubles (or 31%) budget savings for the health care system of the Moscow Region.Conclusion. The implementation of the adapted DRG federal model in the conditions of the health care system of Moscow Region is an economically feasible approach to the organization of the inpatient medical care provided to patients with SA needing bDMDs prescription.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"160 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133778483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-26DOI: 10.17749/2070-4909/farmakoekonomika.2021.063
T. N. Erivantseva, Yu. V. Blokhina
The article provides an overview of the advantages and issues associated with the use of artificial intelligence (AI) and machine learning (ML) in medicine. Based on the analysis of scientific publications, the leading healthcare areas using AI and ML have been identified. The applied problems that modern technologies allow to solve are described, as well as the goals that can be achieved using such technologies. The legal protection issues of technologies using AI are highlighted. A comparison is given of the key aspects of copyright and patent law, and the advantages of patent law and comprehensive patent protection of technologies for process automation in healthcare are presented. The possibilities of complex patent protection and its strategy in the leading areas of AI use in healthcare are considered on specific examples.
{"title":"Artificial intelligence in healthcare: possibilities of patent protection","authors":"T. N. Erivantseva, Yu. V. Blokhina","doi":"10.17749/2070-4909/farmakoekonomika.2021.063","DOIUrl":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.063","url":null,"abstract":"The article provides an overview of the advantages and issues associated with the use of artificial intelligence (AI) and machine learning (ML) in medicine. Based on the analysis of scientific publications, the leading healthcare areas using AI and ML have been identified. The applied problems that modern technologies allow to solve are described, as well as the goals that can be achieved using such technologies. The legal protection issues of technologies using AI are highlighted. A comparison is given of the key aspects of copyright and patent law, and the advantages of patent law and comprehensive patent protection of technologies for process automation in healthcare are presented. The possibilities of complex patent protection and its strategy in the leading areas of AI use in healthcare are considered on specific examples.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116615946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-26DOI: 10.17749/2070-4909/farmakoekonomika.2021.098
E. Pyadushkina, E. Derkach, V. Ignatyeva, E. E. Yagnenkova, T. Klitochenko, Tatiana Shelekhova, A. Levanov
Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured remains open.Objective: to assess the cost of triplets of targeted drugs ixazomib, carfilzomib, elotuzumab and daratumumab with lenalidomide and dexamethasone used in the treatment of RRMM, and to determine possible payment options for this therapy at the level of the Russian Federation subjects.Material and methods. The cost of an annual course of treatment with the studied regimens with centralized purchases and the cost of targeted drugs per hospitalization case were calculated based on the maximum registered prices, recommended doses and treatment regimens. The normative legal acts regulating the payment of drug therapy for multiple myeloma were analyzed and possible financing channels and their limitations were identified. Using the example of the Volgograd and Saratov Regions, tariffs under the compulsory medical insurance system were calculated and their sufficiency in covering the cost of targeted therapy was estimated.Results. The cost of an annual course of triplet therapy per patient in the case of centralized procurement of drugs ranged from 5.51 million rubles (regimen with ixazomib) up to 8.03 million rubles (regimen with carfilzomib). The cost per hospitalization, depending on the number of doses, ranged from 80,667–242,000 rubles (ixazomib, 1–3 doses) in the Saratov Region up to 239,618–958,472 rubles (daratumumab, 1–4 doses) in the Volgograd Region. Possible reimbursement channels are High-Cost Nosologies (HCN), Obligatory Medical Insurance (OMI) and Regional Drug Coverage (RDC) programs, nevertheless triplet therapy cannot be purchased via the single channel and the combination of them is required. It has been shown that, in most cases, the costs for a case of targeted drug treatment in studied regions are covered by the average tariff for the corresponding diagnosis-related group (DRG), except for cases with a maximum duration in a day hospital setting. An analysis of the RDC lists and the procurement of drugs in the studied regimens at the expense of regional budgets showed that lenalidomide, ixazomib, carfilzomib, elotuzumab and daratumumab are included in the restrictive list in regions 77, 74, 66, 63 and 47, but they are purchased only in regions 15, 24, 6, 4 and 6, respectively.Conclusion. The use of a triplet with ixazomib is characterized by the lowest costs, which indicates its greater economic attractiveness relative to carfilzomib, daratumumab and elotuzumab in the treatment of patients with RRMM. The tariffs established in the current DRG model retain the possibility of paying for treatment with the high-cost medicines at the expense of the OMI funds in combination with the HCN or RDC programs. There are reasons to believe that the expansion of the list of 14 HCN program will
{"title":"Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting","authors":"E. Pyadushkina, E. Derkach, V. Ignatyeva, E. E. Yagnenkova, T. Klitochenko, Tatiana Shelekhova, A. Levanov","doi":"10.17749/2070-4909/farmakoekonomika.2021.098","DOIUrl":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.098","url":null,"abstract":"Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured remains open.Objective: to assess the cost of triplets of targeted drugs ixazomib, carfilzomib, elotuzumab and daratumumab with lenalidomide and dexamethasone used in the treatment of RRMM, and to determine possible payment options for this therapy at the level of the Russian Federation subjects.Material and methods. The cost of an annual course of treatment with the studied regimens with centralized purchases and the cost of targeted drugs per hospitalization case were calculated based on the maximum registered prices, recommended doses and treatment regimens. The normative legal acts regulating the payment of drug therapy for multiple myeloma were analyzed and possible financing channels and their limitations were identified. Using the example of the Volgograd and Saratov Regions, tariffs under the compulsory medical insurance system were calculated and their sufficiency in covering the cost of targeted therapy was estimated.Results. The cost of an annual course of triplet therapy per patient in the case of centralized procurement of drugs ranged from 5.51 million rubles (regimen with ixazomib) up to 8.03 million rubles (regimen with carfilzomib). The cost per hospitalization, depending on the number of doses, ranged from 80,667–242,000 rubles (ixazomib, 1–3 doses) in the Saratov Region up to 239,618–958,472 rubles (daratumumab, 1–4 doses) in the Volgograd Region. Possible reimbursement channels are High-Cost Nosologies (HCN), Obligatory Medical Insurance (OMI) and Regional Drug Coverage (RDC) programs, nevertheless triplet therapy cannot be purchased via the single channel and the combination of them is required. It has been shown that, in most cases, the costs for a case of targeted drug treatment in studied regions are covered by the average tariff for the corresponding diagnosis-related group (DRG), except for cases with a maximum duration in a day hospital setting. An analysis of the RDC lists and the procurement of drugs in the studied regimens at the expense of regional budgets showed that lenalidomide, ixazomib, carfilzomib, elotuzumab and daratumumab are included in the restrictive list in regions 77, 74, 66, 63 and 47, but they are purchased only in regions 15, 24, 6, 4 and 6, respectively.Conclusion. The use of a triplet with ixazomib is characterized by the lowest costs, which indicates its greater economic attractiveness relative to carfilzomib, daratumumab and elotuzumab in the treatment of patients with RRMM. The tariffs established in the current DRG model retain the possibility of paying for treatment with the high-cost medicines at the expense of the OMI funds in combination with the HCN or RDC programs. There are reasons to believe that the expansion of the list of 14 HCN program will","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"58 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114924748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-25DOI: 10.17749/2070-4909/farmakoekonomika.2021.082
D. Shchurov, V. Dombrovskiy
Objective: early assessming the clinical and economic efficacy of the thrombodynamics test in infertile patients undergoing treatment with assisted reproductive technologies (ART), as well as the impact of this test on the health care budget of the Russian Federation.Material and methods. The study was carried out on the basis of statistical data on the number of ART cycles, the proportion of patients with hypercoagulation and normocoagulation of blood, data on the clinical effectiveness of ART programs in Russia, including the dependency on the status of blood coagulation, as well as cost data. The analysis was carried out according to three scenarios: 1) thrombodynamics test with subsequent correction of the revealed hypercoagulability status before in vitro fertilization (IVF); 2) thrombodynamics test with the subsequent refusal to perform IVF in patients with hypercoagulability; 3) thrombodynamics test with subsequent correction of the revealed hypercoagulability status before the start of the frozen-thawed embryo transfer. The criteria for clinical effectiveness were the following indicators: the number of children born and the number of potentially saved life years. Clinical and economic efficacy criteria included: total direct medical costs; incremental cost-effectiveness ratio (ICER); changes in the amount of total direct medical costs; resizing effectively and ineffectively spent funds.Results. The use of the thrombodynamics test will potentially increase the number of children born by 21–33 children and the number of years of life saved, with discounting considered, within the range of 923–1448 years per 1000 ART cycles, depending on the study scenario. The smallest ICER values were observed in Scenario 2, and amounted to 112,120 rubles for 1 child born and 2519 rubles for 1 saved year of life. The highest ICER values were obtained in Scenario 1: 275,576 rubles for 1 child born and 6191 rubles for 1 saved year of life. The use of the thrombodynamics test in women with infertility before ART in Russia will require an increase in direct medical costs from 174 to 425 million rubles (by 1–5% of the initial level of costs) in absolute terms, depending on the chosen scenario with a time horizon of 1 year.Conclusion. Due to the expected significant improvement in treatment outcomes and the small amount of additional costs, the introduction of the thrombodynamics test into the routine practice of assessing blood clotting in infertile patients before the start of the ART cycle is potentially cost-effective, but further clinical studies are required for a more accurate economic assessment.
{"title":"Clinical and economic analysis of using the thrombodynamics test in patients undergoing treatment with assisted reproductive technologies in the Russian Federation","authors":"D. Shchurov, V. Dombrovskiy","doi":"10.17749/2070-4909/farmakoekonomika.2021.082","DOIUrl":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.082","url":null,"abstract":"Objective: early assessming the clinical and economic efficacy of the thrombodynamics test in infertile patients undergoing treatment with assisted reproductive technologies (ART), as well as the impact of this test on the health care budget of the Russian Federation.Material and methods. The study was carried out on the basis of statistical data on the number of ART cycles, the proportion of patients with hypercoagulation and normocoagulation of blood, data on the clinical effectiveness of ART programs in Russia, including the dependency on the status of blood coagulation, as well as cost data. The analysis was carried out according to three scenarios: 1) thrombodynamics test with subsequent correction of the revealed hypercoagulability status before in vitro fertilization (IVF); 2) thrombodynamics test with the subsequent refusal to perform IVF in patients with hypercoagulability; 3) thrombodynamics test with subsequent correction of the revealed hypercoagulability status before the start of the frozen-thawed embryo transfer. The criteria for clinical effectiveness were the following indicators: the number of children born and the number of potentially saved life years. Clinical and economic efficacy criteria included: total direct medical costs; incremental cost-effectiveness ratio (ICER); changes in the amount of total direct medical costs; resizing effectively and ineffectively spent funds.Results. The use of the thrombodynamics test will potentially increase the number of children born by 21–33 children and the number of years of life saved, with discounting considered, within the range of 923–1448 years per 1000 ART cycles, depending on the study scenario. The smallest ICER values were observed in Scenario 2, and amounted to 112,120 rubles for 1 child born and 2519 rubles for 1 saved year of life. The highest ICER values were obtained in Scenario 1: 275,576 rubles for 1 child born and 6191 rubles for 1 saved year of life. The use of the thrombodynamics test in women with infertility before ART in Russia will require an increase in direct medical costs from 174 to 425 million rubles (by 1–5% of the initial level of costs) in absolute terms, depending on the chosen scenario with a time horizon of 1 year.Conclusion. Due to the expected significant improvement in treatment outcomes and the small amount of additional costs, the introduction of the thrombodynamics test into the routine practice of assessing blood clotting in infertile patients before the start of the ART cycle is potentially cost-effective, but further clinical studies are required for a more accurate economic assessment.","PeriodicalId":201824,"journal":{"name":"FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133412120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：